Skip to main content
Choose your location
Select the location and the language that you prefer

main content, press tab to continue

The Next Big Thing in Longevity Risks

July 9, 2026

For many insurers and reinsurers, events which change the lifespan of current and future annuitants can influence both capital requirements today and profitability in the future. Whilst it’s never possible to fully predict the future, getting early warning of potential changes in mortality gives providers time to adapt their assumptions, adjust their pricing and minimise balance sheet impacts. In this four-part series, “The Next Big Thing in Longevity”, we explore where some of the big longevity events of the future could arise and provide insights into the early warning signals for which insurers should be vigilant to avoid being caught off-guard by such events.

About our “Dementia” white paper

In the first paper of our four-part series, we consider three sources of potential improvements in dementia-related mortality.

We investigate:

  • the nature, timing and potential impact of emerging treatments for the main causes of dementia: Alzheimer’s disease, vascular dementia and dementia with Lewy bodies,
  • how changes in the diagnosis of dementia (or the underlying conditions) might affect survival periods, and
  • the feasibility and potential impact of preventing the diseases which cause dementia.

Our findings indicate that:

  • Dementia does represent a source of longevity risk for (re)insurers. Novel treatments are the most likely source of short-term mortality improvements.
  • However, potential improvements in dementia mortality don’t currently warrant changes to (re)insurers’ assumptions.
  • Nonetheless, to get early warning of changing dementia-related improvements, (re)insurers’ horizon-scanning activities should focus on monitoring the drug-development pipeline and national policies affecting access to novel medications.

Full citations for the evidence underpinning our work are provided in the white paper.

How do organisations benefit?

Organisations will benefit from this white paper through gaining an improved understanding of the dementia diagnosis and treatment landscape (affecting their current and future pensioners), and of signals to monitor in order to identify as early as possible any future dementia-related shifts in longevity.

Download this whitepaper to read our analysis in full.

To get a copy of the download, please complete the form.

Contacts

Richard Marshall, Senior Director, Insurance Consulting and Technology

Richard Marshall

Senior Director, Insurance Consulting and Technology

Richard Marshall is a Senior Director in WTW’s UK Life Insurance practice and is a subject matter expert in longevity and demographic risks. He leads WTW’s European research into issues affecting longevity and has worked extensively on the design, development and validation of Internal Models of longevity risk. He uses his background in public health to help insurers to understand how and why mortality rates vary over time and to develop credible and realistic scenarios for future mortality improvements with allowance for population behaviours and health economic policies in addition to technological and pharmaceutical advances.
Scott Hamilton, Director, Insurance Consulting and Technology

Scott Hamilton

Director, Insurance Consulting and Technology

Scott Hamilton is a Director in WTW’s UK Life Insurance practice and is a subject matter expert in longevity. He has overseen modelling of and research into the mortality impacts of weight loss drugs, cancer tests and climate scenarios, providing insurers with tangible insights relevant to assumption setting and pricing. Scott has an interest in longevity risk Internal Model development and validation, the behavioural aspects of mortality modelling, and socioeconomic differentials in health outcomes.

Download the full whitepaper here